Dynavax Reports First Quarter 2022 Financial Results ...Middle East

PR Newswire - News
Dynavax Reports First Quarter 2022 Financial Results
First quarter 2022 total revenue of $114.0 million, up 37% from $83.3 million for Q1 2021 HEPLISAV-B® vaccine net product revenue of $20.8 million, up 151% from $8.3 million for Q1 2021 CpG 1018® adjuvant net product revenue of $91.5 million, up 23% from $74.6 million for Q1 2021 Guidance...

Hence then, the article about dynavax reports first quarter 2022 financial results was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dynavax Reports First Quarter 2022 Financial Results )

Apple Storegoogle play

Last updated :

Also on site :